source
- FDA approves Scholar Rock's muscle-targeted SMA therapy IsembyldThe Food and Drug Administration has approved a new medication for spinal muscular atrophy (SMA). The drug, apitegromab marketed as Isembyld, is the first muscle-targeted therapy for the disease.…
- GSK reports 94% response rate for Jideytro in ROS1-positive lung cancer at World ConferenceGSK is moving a newly acquired lung-cancer drug, Jideytro, toward FDA review after presenting data at the World Conference on Lung Cancer. The conference data showed a 94% response rate when Jidey…